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Abstract
Background: Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or
chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the
single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be
associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS.
Methods: We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia
(AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid
leukemia, and 95 healthy controls.
Results: The G/G genotype was significantly more common in MDS patients (47/187; 25.1%) than in controls (6/95;
6.3%) or in patients with other leukemias (101/813; 12.4%) (all P < 0.001). Individuals with the G/G genotype were
more likely than those with other genotypes to have MDS (odd ratio = 4.98; 95% CI = 2.04-12.13). Clinical and
follow up data were available for 112 MDS patients and 186 AML patients. There was no correlation between EPO
promoter genotype and response to therapy or overall survival in MDS or AML. In the MDS group, the GG
genotype was significantly associated with shorter complete remission duration, as compared with the TT
genotype (P = 0.03). Time to neutrophils recovery after therapy was significantly longer in MDS patients with the
G/G genotype (P = 0.02).
Conclusions: These findings suggest a strong association between the rs1617640 G/G genotype and MDS. Further
studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental
toxins or chemotherapy.
Background
Myelodysplastic syndromes (MDS) are a group of clonal
hematopoietic disorders that manifest as ineffective
hematopoiesis with hypercellularity in the bone marrow
but cytopenia in peripheral blood. MDS can affect each
of the three myelopoietic lineages and may progress to
acute myeloid leukemia (AML) in some patients [1].
Prior studies suggest that MDS may be induced by cer-
tain mutagenic environmental or chemotherapeutic
toxins [2,3]; however, the role of genetic factors remains
unclear. In fact, the identification of genes that make
individuals more susceptible to developing MDS could,
for example, provide these high-risk individuals the
option of storing frozen bone marrow or hematopoietic
stem cells prior to receiving chemotherapy, if they need
chemotherapy due to the diagnosis of a cancer in other
organ. In addition, identification of genetic factors that
enhance susceptibility to MDS, which is a devastating
disorder, could suggest mechanistic insights for future
interventions.
Genetic variables that potentially associated with MDS
risk, include polymorphisms in tumor necrosis factor a
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any medium, provided the original work is properly cited.and transforming growth factor b, [4,5] as well as varia-
tions in the genes related to Bloom syndrome [6]. Single
nucleotide polymorphisms (SNPs) have been shown to
influence the risk, progression, or pathology of a num-
ber of blood or lymph diseases. A recent study demon-
strated that the T/T genotype of the rs1617640 SNP,
located in the promoter region of the erythropoietin
(EPO) gene, is significantly associated with diabetic reti-
nopathy and end-stage renal disease in patients with
diabetes [7]. The T allele creates a binding site matches
the EVI1/MEL1 or AP1 enhancer binding site, leading
to increased EPO protein expression. It has been
reported that in individuals with the T/T EPO promoter
genotype the EPO protein concentration is 7.5-fold
higher in vitreous as compared with those with the GG
genotype [7]. Individuals with the G/T genotype are
expected to be in the middle. Ex-vivo expression experi-
ments showed 25-fold higher expression of EPO in con-
structs containing the T in the promoter region of the
EPO gene[7]. Given that EPO is involved in the control
of erythroid and other hematopoietic cell production,
[8-11] and because MDS is characterized by impaired
production of hematopoietic cells and may respond to
EPO therapy, [12-14] we hypothesized that the EPO
promoter SNP may show some association with MDS.
Here we examined the association of the rs1617640 SNP
genotype with MDS in groups of patients with various
leukemias and in healthy control subjects.
Methods
Patient population
MDS patients (n = 187) were compared to a sample of
subjects with AML (n = 257), acute lymphocytic leuke-
mia (ALL; n = 106), chronic lymphocytic leukemia (CLL;
n = 97), and chronic myeloid leukemia (CML; n = 353)
patients, as well as 95 healthy individuals. Patients with
therapy-related MDS were included. The normal control
group was volunteers with median age of 33. The ethnic
background was not recorded, but females comprised
60% of this group. Because we did not have a complete
data on the ethnic background of the MDS patients, we
used patients with various types of leukemias as control
s i n c et h e ya r ec o l l e c t e df r o mt h es a m ei n s t i t u t i o na n d
expected to be of the same ethnic background as the
MDS patients. Complete clinical data was available for a
subset of patients with AML and advanced MDS (n =
182 and 114, respectively). All these patients with clinical
data had de novo AML and MDS. All MDS patients with
clinical data had advanced disease (platelets <100000/μL,
hemoglobin <8, or WBC < 1000/μL). This group of
patients was classified according to the French-Ameri-
can-British (FAB) classification. All AML and MDS
patients were treated at MD Anderson Cancer Center
with standard therapy based on idarubicine + ara-C.
All samples were collected with written informed con-
sent. Samples were collected and work was approved by
Institutional Review Committee.
rs1617640 EPO SNP genotyping
The SNP genotype was determined for each patient and
for normal individuals using TaqMan MGB (minor
groove binding) probes for allele discrimination (Applied
Biosystems, Foster City, CA). Briefly, the rs1617640 EPO
SNP was PCR amplified in the presence of MGB probes
specific for the G and T SNP alleles. Bound probes were
cleaved by the Taq polymerase in the process of PCR
amplification, releasing the reporter dyes. Following
PCR, plates were read using the 7900HT Fast Real-Time
PCR system, and the data were analyzed using Allele
Discrimination software (Applied Biosystems).
Statistical analysis
Patient characteristics were summarized using standard
descriptive statistics for continuous variables and tabula-
tions for categorical variables. Relationships between
continuous variables were assessed with Spearman rank
correlations. Odds ratios and risk ratios with 95% confi-
dence intervals were calculated for each genotype in var-
ious comparisons. Kaplan-Meier plots of complete
remission duration were performed separately for each
diagnostic group.
Results
The G/G genotype is more common in MDS
The distribution of rs1617640 genotypes (G/G, G/T, T/
T) in MDS patients differed significantly from those of
the control and other leukemia groups (Table 1). Except
for the ALL group, which showed a mild increase in the
G/T (58.5%) genotype as compared to the control group
(P = 0.03), there was no significant difference in geno-
type distribution between any of the acute and chronic
leukemia groups, versus control or combined leukemia
groups (Table 1). The P-value in Table 1 was calculated
based on comparing the three genotypes. The genotype
distribution did differ significantly between control sub-
jects and all non-MDS leukemia patients when consid-
ered as a group. Patients with MDS had a higher chance
of having the G/G than did normal control subjects and
patients with other leukemias (Table 2). Patients with
myeloid diseases (AML and CML) and those with CLL
also had slightly greater chance of having the G/G geno-
type than did the healthy control group. The ALL group
showed odd ratio (OR) for the G/G genotype of 2.26
(95% CI = 0.83-6.13), which is similar to that of AML
2.11 (95% CI = 0.85-5.22) (Table 2). The OR for ALL
vs. AML is 1.07 (CI = 0.55-0.99).
In general, in all leukemia patients the ORs of having
the G/G genotype were higher than in healthy control
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raises the possibility that individuals with the G/G geno-
type truly have greater tendency to develop leukemia, or
to an abnormally low proportion of control subjects
having the G/G genotype. With either consideration, the
G/G genotype is particularly associated with MDS.
Clinical Correlations
Complete clinical data were available for a subset of
MDS (n = 114) and AML patients (n = 182). The char-
acteristics of these patients are detailed in Table 3. As
shown in Table 3, the patients in the AML group were
typical adult AML patients. The patients in the MDS
group had advanced disease with significant number
(51%) having refractory anemia with excess blasts in
transformation (RAEB-T). All patients were treated uni-
formly with standard chemotherapy and all patients
were de novo. As shown in Table 4, the odd ratio of
having the G/G genotype in this group of patients were
5.18 for the MDS group and 2.3 for the AML group as
compared with the normal control group. The odds
were significantly higher in the MDS than in the AML
group, but these odds remain high in the AML patients.
The new World Health Organization (WHO) classifica-
tion scheme classifies patients with a blast count
between 20% and 30% as having acute leukemia, while
the previous FAB classification considers these patients
as having MDS with RAEB-T. We therefore evaluated
the G/G genotype in RAEB-T and CMML patients sepa-
rately from the AML patients classified according to the
FAB and from the MDS patients classified according to
the WHO (Table 5). As shown in Table 5, 21% of the
RAEB-T and 27% of the CMML had the G/G genotype,
which suggests that these patients are closer to MDS
than to AML. Patients with high and intermediate II
score on the International Prognostic Scoring System
(IPSS) had a borderline difference in EPO genotype (P =
0.06) as compared with AML, while patients with low
and intermediate I IPSS score had significantly more
GG EPO genotype (P = 0.03). In addition, we investi-
gated if the presence of dysplasia in the patients with
AML is associated with higher rate of G/G genotype.
There was no significant difference in EPO genotype
between cases with multilineage dysplasia versus no dys-
plasia (P = 0.07).
Upon correlating various clinical parameters with
rs1617640 genotype, there was no correlation between
genotypes and survival, response, age, performance sta-
tus, cytogenetics, white blood cell count, platelet count,
level of hemoglobin, creatinine, beta 2-microglobulin,
blood urea nitrogen, and lactate dehydrogenase. How-
ever, we found in MDS patients that neutrophils recov-
ery required significantly longer time if patients had the
G/G genotype as compared with the other genotypes
(P = 0.02) (Figure 1). In addition, the MDS group with
G/G genotype (n = 22) displayed significantly shorter
complete remission duration relative to patients with
the T/T genotype (n = 17) (P = 0.03) (Figure 2). How-
ever, the number of patients is small since only 39
patients achieved complete response. Despite the small
number, we explored the effects of covariates. In multi-
variate analysis incorporating cytogenetic grouping with
EPO polymorphism, EPO polymorphism was no longer
significant while cytogenetic grouping was independent
predictor of early relapse. Irrespective, this observation
suggests that the genotype of the rs1617640 EPO
Table 1 Distribution of rs1617640 EPO SNP genotype in normal control subjects and patients with various
hematologic diseases
EPO SNP Genotype P-value (vs. normal controls)
a P-value (vs. all leukemia samples)
a
Diagnosis G/G G/T T/T Total
Normal n 6 41 48 95
% 6.32 43.2 50.5 0.02
MDS n 47 73 67 187
% 25.1 39 35.8 <.001 <0.001
ALL n 14 62 30 106
% 13.2 58.5 28.3 0.03 0.61
AML n 32 115 110 257
% 12.5 44.8 42.8 0.1 0.21
CLL n1 1 3 4 5 2 9 7
% 11.3 35.1 53.6 0.22 0.31
CML n 44 173 136 353
% 12.5 49 38.5 0.09 0.1
Total n 154 498 443 1095
% 14.1 45.5 40.5 100
aFisher’s exact test.
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confidence intervals (CI) for the EPO SNP rs1617640
healthy control subjects and patients with various
hematologic diseases
Odds Ratio Relative Risk
OR 95% CI RR 95% CI
MDS vs. ALL
G/G 2.2 1.15-4.24 1.28 1.07-1.52
G/T 0.45 0.28-0.74 0.75 0.62-0.90
T/T 1.41 0.84-2.37 1.13 0.95-1.34
MDS vs. AML
G/G 2.36 1.44-3.88 1.55 1.24-1.94
G/T 0.79 0.54-1.16 0.87 0.70-1.09
T/T 0.75 0.56-1.10 0.84 0.67-1.06
MDS vs. CLL
G/G 2.62 1.29-5.33 1.31 1.11-1.54
G/T 1.19 0.71-1.98 1.06 0.89-1.25
T/T 0.48 0.29-0.80 0.77 0.64-0.93
MDS vs. CML
G/G 2.36 1.49-3.72 1.66 1.30-2.11
G/T 0.67 0.47-0.96 0.77 0.60-0.97
T/T 0.89 0.62-1.29 0.93 0.73-1.18
MDS vs. Normal
G/G 4.98 2.04-12.13 1.45 1.26-1.67
G/T 0.84 0.51-1.39 0.94 0.79-1.12
T/T 0.55 0.33-0.90 0.81 0.68-0.97
ALL vs. AML
G/G 1.07 0.55-2.10 1.05 0.66-1.68
G/T 1.74 1.10-2.75 1.48 1.07-2.05
T/T 0.53 0.32-0.86 0.63 0.44-0.91
ALL vs. CLL
G/G 1.19 0.51-2.76 1.08 0.74-1.58
G/T 2.61 1.48-4.61 1.57 1.20-2.06
T/T 0.34 0.19-0.61 0.58 0.42-0.80
ALL vs. CML
G/G 1.07 0.56-2.04 1.05 0.64-1.72
G/T 1.47 0.95-2.27 1.34 0.96-1.89
T/T 0.63 0.39-1.01 0.70 0.48-1.02
ALL vs. Normal
G/G 2.26 0.83-6.13 1.38 1.00-1.90
G/T 1.86 1.06-3.25 1.34 1.02-1.76
T/T 0.39 0.22-0.69 0.62 0.46-0.85
AML vs. CLL
G/G 1.11 0.54-2.30 1.03 0.85-1.24
G/T 1.50 0.92-2.44 1.11 0.98-1.26
T/T 0.65 0.41-1.04 0.89 0.78-1.01
AML vs. CML
G/G 1.00 0.61-1.62 1.00 0.75-1.32
G/T 0.84 0.61-1.16 0.91 0.75-1.09
T/T 1.19 0.86-1.66 1.11 0.92-1.33
AML vs. Normal
G/G 2.11 0.85-5.22 1.18 1.01-1.37
Table 3 Characteristics of the AML and MDS patients
with complete clinical data
Characteristic AML, n = 186 MDS, n = 112
Median age, years (range) 61 (17-84) 65 (21-85)
Performance Status
0-1 127 91
2-4 52 20
Missing 7 1
Cytogenetics,
Favorable 23 0
Unfavorable 57 68
Intermediate 106 44
Missing
Median white blood cell count
(range) × 10
9/L
8.95 (0.5-300.5) 2.9 (0.6-131.4)
Median Hemoglobin, g/dL (range) 7.8 (2.5-13.1) 7.95 (3.6-13.1)
Median Platelets × 10
9/L (range) 54 (4-463) 41.5 (2-307)
LDH (U/L) 930 (262-20701) 636 (245-6285)
FAB classification
M0-2 98
M3 13
M4-5 41
M6/M7 10
Missing 24
RA 3
RARS 3
RAEB 38
RAEB-T 58
CMML 11
Table 2: Odds ratio (OR) and relative risk (RR) and 95%
confidence intervals (CI) for the EPO SNP rs1617640
healthy control subjects and patients with various hema-
tologic diseases (Continued)
G/T 1.07 0.66-1.71 1.02 0.90-1.16
T/T 0.73 0.46-1.17 0.92 0.81-1.05
CLL vs. CML
G/G 0.90 0.44-1.81 0.92 0.52-1.61
G/T 0.56 0.35-0.90 0.63 0.44-0.92
T/T 1.84 1.17-2.90 1.61 1.13-2.29
CLL vs. Normal
G/G 1.90 0.67-5.36 1.32 0.90-1.93
G/T 0.71 0.40-1.27 0.84 0.62-1.14
T/T 1.13 0.64-1.99 1.06 0.80-1.41
CML vs. Normal
G/G 2.11 0.87-5.12 1.13 1.01-1.27
G/T 1.27 0.80-2.00 1.05 0.95-1.16
T/T 0.61 0.39-0.97 0.90 0.81-1.00
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mal hematopoiesis after therapy. It is possible that a dif-
ferent strategy of maintenance therapy should be
considered in these patients, especially since the G/G
genotype of the EPO has been linked to lower levels of
EPO expression relative to the T/T genotype [7]. How-
ever, due to the small number of patients and due to
the analysis of multiple parameters, a confirmation of
clinical correlation in larger studies is needed to rule
out overfitting.
Discussion and conclusions
EPO as a growth factor clearly plays a major role in
hematopoiesis. The EPO expression is regulated through
complex mechanisms and EPO expression is highly con-
trolled due to its known response to hypoxia. The
reported influence of the rs1617640 SNP in the promo-
ter region of the EPO gene on its level of expression,
most likely, makes this SNP relevant to hematopoiesis
as well. Here we report that the G/G genotype of the
rs1617640 SNP is highly associated with MDS, not only
as compared with normal control group, but also as
compared with patients with other types of acute and
chronic leukemias. Unfortunately, the ethnic background
of the MDS patients is not available, therefore, we ana-
lyzed patients seen in the same institution, but present-
ing with a different types of leukemias as a control. We
are comparing MDS patients to AML, ALL, CML, and
AML patients seen in the same institutions. Since none
of these diseases has ethnic bias, therefore they can be
used as a control. While we do not know, at this point,
the mechanism in which this SNP can lead to the devel-
opment of MDS, the remarkable association between
the G/G genotype and MDS suggests a relevance to the
development of MDS. The fact that the G/G genotype is
associated low levels of EPO hormone suggests that low
levels of EPO may play a role in the development of
MDS. Not all G/G genotype patients develop MDS,
therefore, other factors, especially environmental, may
cooperate with the low level of EPO in the development
of MDS. Unfortunately pre-MDS EPO levels are not
available on these patients. Knowing these levels may
provide additional information to better understand the
mechanism in which EPO SNP plays a role in MDS.
The levels of EPO after developing the MDS should also
be studies, however, these levels are influenced by other
factors related to the known heterogeneity between
MDS patients in hemoglobin and white cell count and
may not reflect its role in the development of MDS. It is
possible that long-term low EPO level prior to the
development of MDS disrupts the normal maturation of
hematopoietic cells and eventually leads to neoplasia,
especially when this is combined with exposing these
hematopoietic cells to environmental or therapeutic
toxic agents. In addition, EPO protein is a powerful
angiogenic factor and it is possible that prior to the
development of MDS, there is low angiogenesis in bone
marrow leading to disruption in the normal maturation
and differentiation of hematopoitic cells. Of course
angiogenesis increases after the development of MDS,
but this could be driven by other factors.
While we cannot demonstrate relevance for EPO pro-
moter genotype on outcome in patients with MDS, our
data suggests that neutrophils recovery is slower in
patients with G/G phenotype. The reason for this is
unknown, but it is possible that EPO protein contribute
to the recovery of the neutrophils. There was no corre-
lation between hemoglobin recovery and genotype
despite that the G/G patients express relatively low level
of EPO. The EPO promoter genotype in patients with
MDS has never been considered when patients with
MDS are treated with EPO protein. The recent studies
showed that patients with early MDS may benefit from
EPO therapy, especially those with low EPO levels
[15-17]. Correlating levels of EPO and response to EPO
in MDS patients with EPO promoter genotype may pro-
vide important information that may help stratifying
patients for such therapy. In addition, EPO protein
levels have been implicated in MDS as a cofactor that
determine the manifestation of the disease[18]. In that,
patients with low EPO protein may present with anemia,
Table 4 Odds ratio (OR) and relative risk (RR) and 95%
confidence intervals (CI) for the EPO SNP rs1617640 in
AML and MDS patients with complete clinical data
Odd Ratio 95%CI Risk Ratio 95%CI
MDS vs AML
T/T 0.82 0.51-1.34 0.88 0.65-1.20
G/G 2.25 1.24-4.09 1.58 1.17-2.14
G/T 0.72 0.45-1.17 0.82 0.60-1.11
MDS vs Normal
T/T 0.54 0.31-0.95 0.75 0.57-0.99
G/G 5.18 2.05-13.12 1.72 1.38-2.13
G/T 0.82 0.47-1.43 0.91 0.70-1.18
AML vs Normal
T/T 0.66 0.40-1.09 0.87 0.73-1.03
G/G 2.3 0.91-5.83 1.25 1.03-1.52
G/T 1.13 0.69-1.86 1.04 0.88-1.23
Table 5 Distribution of rs1617640 EPO SNP genotypes in
patients with CMML and RAEB-T as compared to MDS
and AML according to WHO classification
AML MDS (WHO) RAEB-T CMML
G/T, n (%) 86 (46.24) 10 (23.8) 27 (46.55) 6 (54.55)
T/T, n (%) 74 (39.78) 20 (45.45) 19 (32.76) 2 (18.18)
G/G, n (%) 26 (13.98) 14 (31.82) 12 (20.69) 3 (27.27)
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dysplasia but adequate hemoglobin and present only
when the disease is advanced with the presence of sig-
nificant neutropenia[18].
Clearly more studies are needed for confirmation of
our observations, especially with case control and more
detailed racial and environmental data as well as further
analysis of other risk factors. The prevalence of the G/G
Figure 2 Shorter complete remission duration (CRD) in patients with G/G genotype as compared with T/T genotype. Kaplan-Meier plot
showing significant difference in CRD between the two genotypes. Abbreviation: N, Number of patients; E, number of events (relapse).
Figure 1 Longer time to recovery of neutrophils in patients with G/G genotype.
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isolated anemia vs. those who present with neutropenia
should be explores. In addition, studies are needed to
determine the effects of EPO promoter genotype on effi-
cacy of therapy in patients treated with EPO alone or
those treated with methylation inhibitors and whether
EPO should be added to methylation inhibitors in
patients with the G/G genotype. There is also a need to
explore the role of this SNP in other leukemias. At this
point, we can confirm a strong association between the
G/G genotype of the rs1617640 EPO promoter and
MDS, but further investigations of the biological effects
are needed. Our findings could have significant clinical
implications. EPO promoter genotype may influence the
efficacy of therapy, especially when EPO is used in
early-stage MDS patients. Methylation inhibitors, which
are used to treat MDS, may influence the EPO promoter
region, and the role of the rs1617640 SNP should be
investigated in this context. Our findings also raise
questions about the role of the EPO genotype in deter-
mining the clinical value of EPO therapy for ameliora-
tion of anemia and neutropenia in patients with solid
tumors. Given the strong association of the G/G geno-
type of rs1617640 with MDS, analysis of this SNP may
prove to be an important screening tool for high risk
patients before they are exposed to toxic agents, thera-
peutically or environmentally. Clearly, the importance of
SNP genotyping in MDS and other diseases will only
increase as more links to pathology are uncovered. Our
novel finding that the EPO promoter SNP rs1617640 is
associated with a 5-fold excess risk of MDS is an impor-
tant step toward a better understanding of the patho-
genesis of this complex disease.
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